Acetamides

Eisai To Present Latest Data of Lemborexant at 35th Annual Sleep Meeting (SLEEP2021)

Wednesday, June 9, 2021 - 3:31am

TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.

Key Points: 
  • TOKYO, June 9, 2021 - (JCN Newswire) - Eisai Co., Ltd. announced today that a total of 5 poster presentations including the latest data on its in-house discovered orexin receptor antagonist lemborexant (product name: DAYVIGO) will be given at the 35th annual meeting of the Associated Professional Sleep Societies (SLEEP 2021), to be held virtually from June 10 to 13, 2021.
  • Major poster presentations include the results of a study evaluating next-dose transition from zolpidem to lemborexant for insomnia treatment (Poster Numbers: #335 and #337).
  • Eisai considers neurology a therapeutic area of focus.
  • Eisai strives to create innovative products in therapeutic areas with high unmet medical needs as soon as possible, and will further contribute to addressing the diverse needs of, as well as increasing the benefits provided to, those living with neurological diseases and their families.

Strongbridge Biopharma plc Announces Issuance of Patent for RECORLEV® (levoketoconazole) for the Treatment of Cushing’s Syndrome

Thursday, June 3, 2021 - 9:01pm

11,020,393 entitled, Methods of Treating Disease with Levoketoconazole which covers a method of treating Cushings syndrome patients with RECORLEV (levoketoconazole) who also take metformin for Type 2 diabetes.

Key Points: 
  • 11,020,393 entitled, Methods of Treating Disease with Levoketoconazole which covers a method of treating Cushings syndrome patients with RECORLEV (levoketoconazole) who also take metformin for Type 2 diabetes.
  • 9,918,984, covers methods of treating Cushings syndrome with levoketoconazole and will expire on January 10, 2026.
  • RECORLEV is an adrenal steroidogenesis inhibitor with a New Drug Application that is currently under review by the U.S. Food and Drug Administration for the treatment of endogenous Cushings syndrome.
  • RECORLEV has received orphan drug designation from the FDA and theEuropean Medicines Agencyfor the treatment of endogenous Cushing's syndrome.

Promescent Debuts Medical Advisory Board's 'Ask-a-Doctor' Portal

Wednesday, May 26, 2021 - 8:00pm

Introduced in early February 2021, Promescent's Medical Advisory Board provides additional perspectives and years of board-certified expertise to customers, while advising product development strategy and leading medical outreach initiatives.

Key Points: 
  • Introduced in early February 2021, Promescent's Medical Advisory Board provides additional perspectives and years of board-certified expertise to customers, while advising product development strategy and leading medical outreach initiatives.
  • Promescent's Medical Advisory Board will be available through the company's "Ask a Doctor" submission form and corresponding column.
  • The Ask-a-Doctor Portal allows us to offer our customers the same informed opinions that we rely on," says Jeff Abraham, CEO of Promescent.
  • Absorption Pharmaceuticals is the maker of Promescent, a lidocaine spray made with careful consideration for the people who use it.

Global $2.09 Billion Chitosan Market Size, Trends & Growth to 2028 by Grade, Source, Application, and Region - ResearchAndMarkets.com

Thursday, May 6, 2021 - 2:46pm

b'The "Chitosan Market Size, Trends & Growth, By Grade, By Source, By Application, And By Region, Forecast To 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global chitosan market size is expected to reach USD 2,093.5 Million in 2028, and register a CAGR of 12.9% during the forecast period.\nGrowing awareness regarding health benefits of chitosan and increasing prevalence of various diseases are key factors driving market revenue growth.

Key Points: 
  • b'The "Chitosan Market Size, Trends & Growth, By Grade, By Source, By Application, And By Region, Forecast To 2028" report has been added to ResearchAndMarkets.com\'s offering.\nThe global chitosan market size is expected to reach USD 2,093.5 Million in 2028, and register a CAGR of 12.9% during the forecast period.\nGrowing awareness regarding health benefits of chitosan and increasing prevalence of various diseases are key factors driving market revenue growth.
  • Increasing use of chitosan as one of the essential ingredients in dietary supplements.\nChitosan is polysaccharide chitin derivative sourced from crustacean shell waste such as from lobsters, shrimps, prawns, crabs, as well as white mushrooms.
  • In gastrointestinal (GI) tract, chitosan helps restrict lipid absorption, thus, it is highly preferred to be added in dietary supplements.
  • Chitosan has non-toxic properties which are extremely useful industrial activities such as water purification and other water treatment processes.

FDA Accepts Amgen's Supplemental New Drug Application For Otezla® (apremilast) For Adults With Mild-To-Moderate Plaque Psoriasis

Wednesday, May 5, 2021 - 2:00pm

The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2021.\n"Otezla has been prescribed to hundreds of thousands of patients with moderate-to-severe plaque psoriasis.

Key Points: 
  • The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of December 19, 2021.\n"Otezla has been prescribed to hundreds of thousands of patients with moderate-to-severe plaque psoriasis.
  • The study randomized 595 patients 1:1 to receive Otezla (n=297) 30 mg twice daily or placebo (n=298) for the first 16 weeks.
  • PDE4 inhibition results in increased intracellular cAMP levels, which is thought to indirectly modulate the production of inflammatory mediators.
  • Depression was reported as serious in 0.1% (1/1308) of patients exposed to Otezla, compared to none in placebo-treated patients (0/506).

BioCryst to Present at Upcoming Investor Conferences

Wednesday, May 5, 2021 - 12:00pm

b'RESEARCH TRIANGLE PARK, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., May 05, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the Bank of America 2021 Healthcare Conference on Wednesday, May 12, 2021 at 12:30 p.m.
  • ET and the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021 at 1:20 p.m.
  • ET.
  • RAPIVAB\xc2\xae (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

BioCryst to Report First Quarter 2021 Financial Results on May 6

Thursday, April 22, 2021 - 12:00pm

b'RESEARCH TRIANGLE PARK, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021.\nBioCryst management will host a conference call and webcast at 8:30 a.m.

Key Points: 
  • b'RESEARCH TRIANGLE PARK, N.C., April 22, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2021 financial results on Thursday, May 6, 2021.\nBioCryst management will host a conference call and webcast at 8:30 a.m.
  • ET that day to discuss the financial results and provide a corporate update.\nThe live call may be accessed by dialing 877-303-8027 for domestic callers and 760-536-5165 for international callers and using conference ID # 2660434.
  • A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com .
  • RAPIVAB\xc2\xae (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.

Scilex Holding, a Subsidiary of Sorrento, Has Received From FDA a sNDA Approval for ZTlido® Label Expansion

Friday, April 9, 2021 - 8:00pm

PALO ALTO, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding (Scilex), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, Sorrento), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido to make efficacy labeling change with clinical data.

Key Points: 
  • PALO ALTO, Calif., April 09, 2021 (GLOBE NEWSWIRE) -- Scilex Holding (Scilex), an over 99% owned subsidiary of Sorrento Therapeutics (NASDAQ: SRNE, Sorrento), has received a supplemental new drug application (sNDA) approval from the FDA for ZTlido to make efficacy labeling change with clinical data.
  • ZTlido is the only lidocaine topical system that has been studied under the water stress conditions, and now has FDA label reflecting its use while showering, swimming and bathing.
  • The trial showed that the topical system may be used while showering and that this does not increase lidocaine plasma levels.
  • Scilex Holding Company, a majority-owned subsidiary of Sorrento, is a commercial-stage, non-opioid pain management company focused on the development and commercialization of topical and injectable therapies.

2021 Global Piracetam (CAS 7491-74-9) Market Research Report - Key Industry Trends - ResearchAndMarkets.com

Friday, April 9, 2021 - 12:49pm

The "Piracetam (CAS 7491-74-9) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Piracetam (CAS 7491-74-9) Global Market Research Report 2021" report has been added to ResearchAndMarkets.com's offering.
  • This global report is a result of industry experts' diligent work on researching the world market of Piracetam.
  • The report helps to build up a clear view of the market trends and development, identify major players in the industry, and estimate main downstream sectors.
  • The Piracetam global market report key points:

BioCryst to Present at 20th Annual Needham Virtual Healthcare Conference

Wednesday, April 7, 2021 - 12:00pm

RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., April 07, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the company will present at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 8:45 a.m.
  • BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease.
  • RAPIVAB(peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea.
  • For more information, please visit the companys website at www.biocryst.com .